Exploring WRN Inhibition in MSI Tumors to Expand Synthetic Lethality Strategies Beyond PARP

• See how the MD Anderson Cancer Center is advancing first-in-human trial data for WRN inhibitors in MSI solid tumors

• Interpreting translational relevance and biomarker integration

• Positioning WRN as a synthetic lethality target beyond PARP